The privately held precision immunotherapy company Alithea Bio UG was founded in 2019 in Freiburg, Germany. Its main goal is the support innovativations like TCR T cell therapy and cancer vaccines. Alithea is partnering its highly sensitive and highly reproducible mass spectrometric assays for HLA-peptide profiling M-zoom, such as NeoZoom for neoantigen detection. Further, Alithea has a unique high-quality database of HLA ligands based on a unified bioinformatics pipeline revealing >1'000'000 HLA ligands in a broad range of indications for target discovery and off target expression screening. In addition, Alithea is working on the development of precision medicine strategies for immuotherapy based on a HLA biomarker platform.